aztreonam has been researched along with kanamycin a in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ayala, JA; Casellas, JM; Di Conza, J; Ghiglione, B; Gutkind, G; Power, P; Radice, M; Rodríguez, MM | 1 |
| Castanheira, M; Jones, RN; Mendes, RE; Sader, HS; Toleman, MA; Walsh, TR | 1 |
| Chen, YT; Lauderdale, TL; Liao, TL; Shiau, YR; Shu, HY; Su, IJ; Tsai, SF; Wu, KM; Yan, JJ | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Badur, S; Cagatay, AA; Carrër, A; Eraksoy, H; Nordmann, P; Poirel, L | 1 |
| Kirikae, T; Kitao, T; Miyoshi-Akiyama, T | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Hayashi-Nishino, M; Nishino, K; Yamaguchi, A; Yamasaki, S | 1 |
| Galleni, M; Gutkind, G; Power, P; Rodríguez, MM; Sader, H | 1 |
| Bogaerts, P; Buvens, G; Glupczynski, Y; Lauwers, S; Piérard, D | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bollinger, M; Compton, J; Greenberg, RN | 1 |
| Husson, M; Klastersky, J; Van Laethem, Y | 1 |
| Buesing, MA; Jorgensen, JH | 1 |
| Aronoff, SC; Klinger, JD | 1 |
1 review(s) available for aztreonam and kanamycin a
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
15 other study(ies) available for aztreonam and kanamycin a
| Article | Year |
|---|---|
Biochemical characterization of PER-2 and genetic environment of blaPER-2.
Topics: Amino Acid Sequence; Base Sequence; beta-Lactam Resistance; beta-Lactamases; Catalysis; Citrobacter freundii; Conjugation, Genetic; DNA, Bacterial; DNA, Recombinant; Enterobacteriaceae; Genes, Bacterial; Humans; Hydrolysis; Isoelectric Focusing; Kinetics; Mass Spectrometry; Microbial Sensitivity Tests; Molecular Sequence Data; Molecular Weight; Plasmids; Polymerase Chain Reaction; Promoter Regions, Genetic; Protein Conformation; Protein Sorting Signals; Sequence Analysis, DNA | 2007 |
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
Topics: Acinetobacter; Amino Acid Sequence; Aminoglycosides; Anti-Bacterial Agents; Base Sequence; Brazil; Codon, Terminator; Cross Infection; Drug Resistance, Multiple, Bacterial; Gene Transfer, Horizontal; Genes, Bacterial; Hospitals; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Open Reading Frames; Plasmids; Pseudomonas putida; Transcription, Genetic | 2007 |
Sequencing and comparative genomic analysis of pK29, a 269-kilobase conjugative plasmid encoding CMY-8 and CTX-M-3 beta-lactamases in Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Conjugation, Genetic; Genomics; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Sequence Analysis, DNA | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
Topics: Bacterial Proteins; beta-Lactamases; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Models, Genetic; Turkey | 2008 |
AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
Topics: Acetylation; Acetyltransferases; Aminoglycosides; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Integrons; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Copper; Drug Resistance, Bacterial; Drug Resistance, Multiple; Escherichia coli; Escherichia coli Proteins; Gene Expression Regulation, Bacterial; Lipoproteins; Membrane Transport Proteins; Microbial Sensitivity Tests; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Novel chromosome-encoded CTX-M-78 beta-lactamase from a Kluyvera georgiana clinical isolate as a putative origin of CTX-M-25 subgroup.
Topics: Ampicillin; Anti-Bacterial Agents; beta-Lactamases; Chromosomes, Bacterial; Gentamicins; Humans; Kluyvera; Male; Microbial Sensitivity Tests; Middle Aged; Nalidixic Acid; Sulfamethoxazole; Trimethoprim | 2010 |
Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum β-lactamase in serogroup O26.
Topics: Adhesins, Bacterial; Anti-Bacterial Agents; beta-Lactamases; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Proteins; Humans; Plasmids; Shiga Toxins | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
Synergistic activity of amikacin with aztreonam against Pseudomonas aeruginosa and other gram-negative organisms.
Topics: Amikacin; Aztreonam; Drug Synergism; Gram-Negative Bacteria; Kanamycin; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 1986 |
Serum bactericidal activity of aztreonam, cefoperazone, and amikacin, alone or in combination, against Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, and Pseudomonas aeruginosa.
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Bacteria; Bacteriological Techniques; Cefoperazone; Drug Therapy, Combination; Escherichia coli; Humans; Kanamycin; Klebsiella pneumoniae; Pseudomonas aeruginosa; Serratia marcescens; Time Factors | 1984 |
In vitro activity of aztreonam in combination with newer beta-lactams and amikacin against multiply resistant gram-negative bacilli.
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Drug Resistance, Microbial; Drug Synergism; Gram-Negative Bacteria; Humans; Kanamycin; Microbial Sensitivity Tests | 1984 |
In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis.
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Child; Cystic Fibrosis; Drug Therapy, Combination; Humans; Kanamycin; Penicillin Resistance; Piperacillin; Pseudomonas Infections; Ticarcillin | 1984 |